| MOLMED SPA Patent applications |
| Patent application number | Title | Published |
|---|
| 20110263512 | CONJUGATES FOR THE TREATMENT OF MESOTHELIOMA - The present invention provides conjugates of cytokines and targeting peptides that is able to bind to a receptor expressed on tumor-associated vessels or to a component of the extracellular matrix associated to the tumor vessels, for treatment of malignant pleural mesothelioma. In particular, the invention provides conjugates comprising the cytokine TNF linked to a peptide containing the NGR motif. The invention further provides pharmaceutical compositions comprising such conjugate and pharmaceutical formulations comprising conjugates dissolved in appropriate buffers. | 10-27-2011 |
| 20110076234 | PEPTIDES COMPRISING AN ISODGR MOTIF - Disclosed herein are peptides which include an isoDGR motif and which selectively inhibit αvβ3 integrin. In some embodiments, the isoDGR motif results from the deamidation of an NGR motif. | 03-31-2011 |
| 20100310506 | Immunoconjugates for the Treatment of Tumours - A pharmaceutical composition comprising a conjugate of a cytokine and a tumor targeting moiety (TTM) and a pharmaceutically acceptable excipient, wherein the cytokine is present in an amount which does not induce a negative feedback mechanism. | 12-09-2010 |
| 20090130069 | Thymidine Kinase - A polynucleotide comprising a nucleotide sequence encoding a thymidine kinase wherein at least one of the nucleotides corresponding to the splice donor site nucleotides is replaced by another nucleotide and wherein the nucleotides of the splice acceptor sites are not altered. | 05-21-2009 |
| 20090068106 | Conjugation Product - A peptide which selectively inhibits α | 03-12-2009 |
| 20080286305 | Antigen Transduced T Cells Used as a Delivery System for Antigens - A delivery system comprising a T cell comprising at least one antigen capable of loading antigen-presenting-cells with the antigen. | 11-20-2008 |
| 20080286248 | Hiv Vif Mutants - A polynucleotide comprising a nucleotide sequence encoding Vif, wherein each of the amino acids corresponding to positions 127, 128, 130, 131, 132 and 142 of the amino acid sequence in FIG. | 11-20-2008 |
